<DOC>
	<DOCNO>NCT00817336</DOCNO>
	<brief_summary>N-methyl-D-aspartate ( NMDA ) -type glutamate receptor think play pivotal role neurocognitive dysfunction associate schizophrenia . Further , several novel glutamate-based class compound presently development potential novel treatment persistent negative cognitive symptom . The study assess effectiveness NMDA-based intervention biomarkers relate schizophrenia mechanism develop appropriate outcome battery future trial novel compound .</brief_summary>
	<brief_title>Biomarkers Schizophrenia</brief_title>
	<detailed_description>16 in- outpatient DSM-IV-TR schizophrenia schizoaffective disorder prominent negative symptom recruit study . This study consist randomized trial D-serine ( 60 mg/kg/d ) vs. placebo use crossover design 2-week baseline lead-in , two 6-week intervention arm separate two week , placebo control washout period . Biomarkers assess baseline treatment arm , acutely ( day 7 ) follow treatment initiation , follow 6 week treatment ( 6 biomarker session total ) . Primary biomarker outcome measure include 1 ) amplitude mismatch negativity ( MMN ) waveform 2 ) amplitude visual P1 potential . Symptomatic outcome measure include PANSS composite score MATRICS neuropsychological battery . The study support ongoing NIMH-funded Cooperative Drug Development Grant ( CDDG ) PI .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>Inclusion criterion : Age 1864 SCID diagnosis Schizophrenia Schizoaffective Disorder . PANSS 3 factor negative symptom ( screen baseline visit 1 visit 3 ) score &gt; 20 PANSS total score 60110 . Any degree positive symptom acceptable total PANSS score must exceed 110 . SAS total score less equal 12 Calgary Depression Inventory total score less equal 10 suicide ( item 8 ) less moderate ( &lt; 2 ) . Two consecutive CGI rating screen baseline ( visit 1 3 ) change score . Estimated Glomerular Filtration Rate ( GFR ) ( measure renal function ) great equal 60 . Exclusion criterion : Organic brain disorder , include epilepsy ; mental retardation ; medical condition whose pathology treatment would likely alter presentation treatment schizophrenia significantly increase risk associate propose treatment Current DSMIV diagnosis drug/alcohol abuse last month current DSMIV diagnosis drug/alcohol dependence last 6 month Pregnant female patient Impaired renal function Significant extrapyramidal symptom ( reflect total score 10 SAS scale ) , depressive symptom ( reflect score 10 Calgary Depression Scale Schizophrenia ) Patients unable unwilling participate Cognitive assessment ( MATRICS ) electrophysiology task . Patients clozapine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>biomarker</keyword>
	<keyword>EEG</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>NMDA</keyword>
	<keyword>D-serine</keyword>
</DOC>